HCC-话题@MedSci

#HCC#

115篇内容 | 6627人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259542, encodeId=fb72125954230, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素, objectType=article, longId=217877, objectId=804521e8770c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=804521e8770c, replyNumber=0, likeNumber=112, createdTime=2021-09-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=804521e8770c, moduleTitle=Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=804521e8770c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259541, encodeId=316c1259541a6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, objectType=article, longId=217593, objectId=2b2621e5937a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2621e5937a, replyNumber=0, likeNumber=88, createdTime=2021-09-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2621e5937a, moduleTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2621e5937a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259540, encodeId=952f12595401c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, objectType=article, longId=216224, objectId=35e921622426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35e921622426, replyNumber=0, likeNumber=104, createdTime=2021-08-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35e921622426, moduleTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35e921622426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259539, encodeId=ced012595391b, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:MRI，让增殖型HCC“一眼到底”！, objectType=article, longId=216117, objectId=2d0a21611e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0a21611e9b, replyNumber=0, likeNumber=104, createdTime=2021-08-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0a21611e9b, moduleTitle=Radiology:MRI，让增殖型HCC“一眼到底”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0a21611e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259538, encodeId=69fc1259538d7, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, objectType=article, longId=214858, objectId=0b4121485899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4121485899, replyNumber=0, likeNumber=91, createdTime=2021-07-28, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4121485899, moduleTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4121485899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259537, encodeId=2e37125953e9c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：在预测HCC微血管浸润方面，MR并非想象中的可靠！, objectType=article, longId=214714, objectId=ba2c214e1427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba2c214e1427, replyNumber=0, likeNumber=102, createdTime=2021-07-25, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba2c214e1427, moduleTitle=Radiology：在预测HCC微血管浸润方面，MR并非想象中的可靠！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba2c214e1427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259536, encodeId=81c51259536b3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, objectType=article, longId=214189, objectId=ceaa214189f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ceaa214189f7, replyNumber=0, likeNumber=75, createdTime=2021-07-15, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ceaa214189f7, moduleTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ceaa214189f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259535, encodeId=d1fc125953528, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=62, createdTime=2021-07-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259534, encodeId=22b61259534fc, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:对于HCC的诊断，不要只看动脉期！, objectType=article, longId=212732, objectId=4162212e3259, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4162212e3259, replyNumber=0, likeNumber=92, createdTime=2021-06-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4162212e3259, moduleTitle=Radiology:对于HCC的诊断，不要只看动脉期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4162212e3259)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259533, encodeId=a2d4125953320, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:WHO引入了HCC新分型？快来看看它长什么样！ , objectType=article, longId=212528, objectId=6bb22125289a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bb22125289a, replyNumber=0, likeNumber=87, createdTime=2021-06-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bb22125289a, moduleTitle=Radiology:WHO引入了HCC新分型？快来看看它长什么样！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bb22125289a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259532, encodeId=e4651259532c5, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用, objectType=article, longId=212482, objectId=d29f212482ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d29f212482ea, replyNumber=0, likeNumber=96, createdTime=2021-06-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d29f212482ea, moduleTitle=Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d29f212482ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259531, encodeId=8db5125953150, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, objectType=article, longId=212415, objectId=b72721241538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b72721241538, replyNumber=0, likeNumber=81, createdTime=2021-06-09, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b72721241538, moduleTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b72721241538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259530, encodeId=cc22125953074, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, objectType=article, longId=211682, objectId=d50921168225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50921168225, replyNumber=0, likeNumber=93, createdTime=2021-05-24, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50921168225, moduleTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50921168225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259529, encodeId=659812595297f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=80, createdTime=2021-05-22, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259528, encodeId=f511125952812, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=88, createdTime=2021-05-21, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259527, encodeId=df75125952ef4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=87, createdTime=2021-05-20, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259526, encodeId=031b125952633, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！, objectType=article, longId=210866, objectId=2f0121086637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0121086637, replyNumber=0, likeNumber=112, createdTime=2021-05-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0121086637, moduleTitle=Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0121086637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259525, encodeId=bf98125952536, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：放射组学在预测早期HCC复发中的应用, objectType=article, longId=210836, objectId=ae51210836aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae51210836aa, replyNumber=0, likeNumber=98, createdTime=2021-05-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae51210836aa, moduleTitle=Radiology：放射组学在预测早期HCC复发中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae51210836aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259524, encodeId=6a96125952439, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现, objectType=article, longId=210789, objectId=6ad8210e89ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad8210e89ae, replyNumber=0, likeNumber=124, createdTime=2021-05-05, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad8210e89ae, moduleTitle=Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad8210e89ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259523, encodeId=b8e31259523ef, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, objectType=article, longId=210100, objectId=8451210100cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8451210100cd, replyNumber=0, likeNumber=83, createdTime=2021-04-19, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8451210100cd, moduleTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8451210100cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素

2021-09-30

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期

2021-09-26

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！

2021-08-25

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:MRI，让增殖型HCC“一眼到底”！

2021-08-23

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法

2021-07-28

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：在预测HCC微血管浸润方面，MR并非想象中的可靠！

2021-07-25

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果

2021-07-15

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-07-03

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:对于HCC的诊断，不要只看动脉期！

2021-06-16

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:WHO引入了HCC新分型？快来看看它长什么样！

2021-06-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用

2021-06-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。

2021-06-09

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果

2021-05-24

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-05-22

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2021-05-21

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-05-20

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！

2021-05-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：放射组学在预测早期HCC复发中的应用

2021-05-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现

2021-05-05

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要

2021-04-19

科室
- - 订阅+
  - 更多科室
工具
服务